Market Overview

Why Cardiff Oncology's Stock Is Trading Higher Today


Cardiff Oncology (NASDAQ: CRDF) shares are trading higher on Thursday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $27 price target.

Cardiff Oncology Inc is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Its objective is to overcome resistance, extend duration of response and increase overall survival.

Cardiff Oncology shares traded up 10.07% to $13.23 on Thursday at the time of publication. The stock has a 52-week high of $18.12 and a 52-week low of 70 cents.

Latest Ratings for CRDF

Oct 2020HC Wainwright & Co.Initiates Coverage OnBuy
Oct 2020Piper SandlerInitiates Coverage OnOverweight
Sep 2020Maxim GroupMaintainsBuy

View More Analyst Ratings for CRDF
View the Latest Analyst Ratings


Related Articles (CRDF)

View Comments and Join the Discussion!

Posted-In: why it's movingInitiation Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at